Cataracts, a common eye condition characterized by clouding of the lens, often lead to blurred vision and, if left untreated, ...
Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily ...
She learned that she would have to try, and "fail," on two other drugs before Medicare would cover the new one.
Children who develop multiple sclerosis appear to fare better if they were exposed to safe amounts of summer sunshine as ...
Multiple sclerosis (MS) is a disease that affects the brain and spinal cord. It happens when the body’s immune system ...
We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...
The company is expecting 2025 EPS to range from $15.25 to $16.25, below the $16.33 FactSet consensus. Revenue is expected to decline by a mid-single-digit percent on a constant currency basis, as ...
Biogen forecast 2025 profit below last year's levels and Wall Street expectations on Wednesday, hurt by a strong dollar and ...
Cosmos Health (COSM) announced the filing of a patent application for treatment for multiple sclerosis, a disabling autoimmune disorder ...
Beta interferon should not be given to NHS patients with multiple sclerosis, the National Institute ... been pinning their hopes on obtaining the drug. In November, the final appraisal on the ...
The exact cause of MS is unknown, but it is thought US, NY, UNITED STATES, January 31, 2025 /EINPresswire / -- Multiple Sclerosis Ms Drugs market industry Overview 2025 By Drug Class (Disease ...
Researchers have made more advancements in multiple sclerosis in the last five years ... at a time when we have so many disease-modifying medications that were just not available a few decades ...